Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Naphthoquinones | 7 | 2013 | 36 | 1.650 |
Why?
|
| Emetine | 5 | 2017 | 13 | 1.370 |
Why?
|
| Prostatic Neoplasms | 9 | 2024 | 935 | 1.090 |
Why?
|
| Drug Design | 6 | 2016 | 162 | 0.730 |
Why?
|
| Trypanocidal Agents | 2 | 2016 | 39 | 0.530 |
Why?
|
| Trypanosoma cruzi | 2 | 2016 | 149 | 0.490 |
Why?
|
| Androgens | 2 | 2011 | 89 | 0.440 |
Why?
|
| Cytotoxins | 1 | 2012 | 11 | 0.410 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 364 | 0.390 |
Why?
|
| Benzoxazoles | 1 | 2011 | 9 | 0.390 |
Why?
|
| Oxazoles | 1 | 2011 | 19 | 0.380 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 2231 | 0.380 |
Why?
|
| Indazoles | 1 | 2009 | 9 | 0.360 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2009 | 22 | 0.350 |
Why?
|
| Antineoplastic Agents | 6 | 2024 | 803 | 0.350 |
Why?
|
| Structure-Activity Relationship | 6 | 2017 | 409 | 0.330 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2012 | 83 | 0.310 |
Why?
|
| Prodrugs | 2 | 2017 | 24 | 0.290 |
Why?
|
| Liver | 1 | 2009 | 479 | 0.280 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2024 | 4 | 0.250 |
Why?
|
| Antigens, Surface | 1 | 2024 | 43 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 29 | 0.230 |
Why?
|
| Benzamides | 3 | 2010 | 78 | 0.210 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 433 | 0.210 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1198 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 3 | 2024 | 661 | 0.180 |
Why?
|
| Nanoparticles | 1 | 2024 | 318 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 2 | 2017 | 118 | 0.160 |
Why?
|
| Apoptosis | 4 | 2015 | 1398 | 0.150 |
Why?
|
| Male | 10 | 2024 | 20025 | 0.150 |
Why?
|
| Humans | 14 | 2024 | 37093 | 0.140 |
Why?
|
| Gelatinases | 1 | 2016 | 8 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 38 | 0.130 |
Why?
|
| Ditiocarb | 1 | 2015 | 4 | 0.130 |
Why?
|
| Tubulin | 1 | 2016 | 88 | 0.130 |
Why?
|
| Chagas Disease | 1 | 2016 | 98 | 0.130 |
Why?
|
| Molecular Structure | 5 | 2017 | 492 | 0.130 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2010 | 16 | 0.110 |
Why?
|
| Molecular Conformation | 1 | 2013 | 152 | 0.110 |
Why?
|
| Crystallography, X-Ray | 2 | 2011 | 265 | 0.110 |
Why?
|
| Electrons | 1 | 2013 | 68 | 0.110 |
Why?
|
| Hydrolysis | 1 | 2012 | 99 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2016 | 517 | 0.100 |
Why?
|
| NIH 3T3 Cells | 1 | 2012 | 61 | 0.100 |
Why?
|
| Mice | 4 | 2024 | 5913 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2017 | 113 | 0.090 |
Why?
|
| Mice, Nude | 2 | 2024 | 337 | 0.090 |
Why?
|
| Cell Death | 1 | 2011 | 267 | 0.090 |
Why?
|
| Nandrolone | 1 | 2008 | 6 | 0.080 |
Why?
|
| Androgen Antagonists | 1 | 2008 | 18 | 0.080 |
Why?
|
| Benzopyrenes | 1 | 2006 | 6 | 0.070 |
Why?
|
| Animals | 4 | 2024 | 15081 | 0.070 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2005 | 6 | 0.070 |
Why?
|
| Vinyl Compounds | 1 | 2005 | 5 | 0.070 |
Why?
|
| Deoxyguanosine | 1 | 2006 | 35 | 0.070 |
Why?
|
| DNA Adducts | 1 | 2006 | 42 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2005 | 34 | 0.070 |
Why?
|
| Cyclohexanones | 1 | 2004 | 3 | 0.060 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2004 | 11 | 0.060 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2003 | 14 | 0.060 |
Why?
|
| Imides | 1 | 2003 | 9 | 0.060 |
Why?
|
| Cell Survival | 3 | 2015 | 864 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 259 | 0.060 |
Why?
|
| Zebrafish | 1 | 2024 | 128 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 73 | 0.050 |
Why?
|
| Cell Cycle | 3 | 2010 | 326 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2003 | 131 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2003 | 120 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2010 | 859 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 461 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 1502 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2009 | 399 | 0.040 |
Why?
|
| Software | 1 | 2017 | 217 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 269 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2016 | 59 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1039 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 1180 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 626 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 108 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 807 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 8 | 0.020 |
Why?
|
| Formazans | 1 | 2008 | 5 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 41 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 36 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 502 | 0.020 |
Why?
|
| Fluorescence Polarization | 1 | 2008 | 30 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 448 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 623 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2008 | 126 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 27 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 81 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2005 | 9 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 578 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 103 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1207 | 0.020 |
Why?
|
| Catalysis | 1 | 2004 | 179 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 562 | 0.010 |
Why?
|